Journal Article: “Availability of Research Articles For The Public During Pandemic – A Case Study”
The articled linked to below was recently published by LIBER Quarterly, the Journal of the Association on European Research Libraries.
Memorial University of Newfoundland
LIBER Quarterly, 30(1) (2020)
The coronavirus 2019 (COVID-19) disease has affected millions of lives, forcing most of us to stay at home and work. However, there is an immediate need to conduct research on potential drugs against COVID-19. In this article, the extent to which major publishers have provided access for the public to read research articles relevant to potential drug candidates for the COVID-19 disease are presented.
A systematic search of five electronic databases (Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, Wiley, and New England Journal of Medicine (NEJM)) was conducted on April 12-17, 2020. The total number of research articles containing terms ‘Ribavirin’, ‘Remdesivir’, ‘Hydroxychloroquine OR Chloroquine’, ‘Favipiravir’, ‘Lopinavir OR Ritonavir’, ‘Sarilumab’, and ‘Tocilizumab’, available for the public to read for free were determined. In this study, there was a lack of full access to research articles related to potential drugs of COVID-19 in commercial academic databases, except for ‘Remdesivir’ and ‘Favipiravir’ from NEJM.
Direct to Full Text Article
About Gary Price
Gary Price (email@example.com) is a librarian, writer, consultant, and frequent conference speaker based in the Washington D.C. metro area. He earned his MLIS degree from Wayne State University in Detroit. Price has won several awards including the SLA Innovations in Technology Award and Alumnus of the Year from the Wayne St. University Library and Information Science Program. From 2006-2009 he was Director of Online Information Services at Ask.com. Gary is also the co-founder of infoDJ an innovation research consultancy supporting corporate product and business model teams with just-in-time fact and insight finding.